ABSTRACT
BACKGROUND: Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial: Subject(s)
Cisplatin
, Urinary Bladder Neoplasms
, Humans
, Neoadjuvant Therapy/methods
, Gemcitabine
, Nivolumab/therapeutic use
, Proteomics
, Tumor Microenvironment
, Urinary Bladder Neoplasms/drug therapy
, Urinary Bladder Neoplasms/pathology
, Biomarkers, Tumor
, Muscles/pathology
, Immunotherapy
, Neoplasm Invasiveness
, Cystectomy